PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH NON-HODGKINS-LYMPHOMA TREATED WITH CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISONE, BLEOMYCIN, ADRIAMYCIN, PROCARBAZINE (COP-BLAM) THERAPY

Authors
Citation
N. Niitsu, PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH NON-HODGKINS-LYMPHOMA TREATED WITH CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISONE, BLEOMYCIN, ADRIAMYCIN, PROCARBAZINE (COP-BLAM) THERAPY, Acta haematologica, 98(3), 1997, pp. 130-135
Citations number
18
Categorie Soggetti
Hematology
Journal title
ISSN journal
00015792
Volume
98
Issue
3
Year of publication
1997
Pages
130 - 135
Database
ISI
SICI code
0001-5792(1997)98:3<130:PFIEPW>2.0.ZU;2-O
Abstract
Elderly patients with non-Hodgkin's lymphoma (NHL) were treated with c yclophosphamide, vincristine, prednisone, bleomycin, Adriamycin, proca rbazine (COP-BLAM) therapy at our institution. Prognostic factors were analyzed in 62 patients with untrated NHL aged 65 years or older. Of these patients, 47 (75.8%) achieved a complete remission and 11 (17.7% ) partial remission. The overall response rate was 93.5%, with a 5-yea r survival rate of 70%. Factors with prognostic significance included age, performance status, albumin, stage, B symptoms, and histologic ty pe according to the International Working Formulation. Of the 62 patie nts, 26 were alive at the time of writing. Of the 36 patients who died , 30 died due to progression of NHL or treatment-related disorders, an d 6 died from disease other than NHL. Some of the prognostic factors i dentified in these elderly patients are not included among the prognos tic factors reported for younger patients, suggesting the need to indi vidualize chemotherapy for NHLs of different types, which can be defin ed by prognostic factors. Prognostic factors other than age should be taken into account, particularly when doses and dosing intervals are d etermined.